Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided content correctly reflects key FDA label excerpts on approved route (IV-only, not intrathecal), recommended dose (0.1 mmol/kg), and the boxed/warning-relevant risks regarding intrathecal use and nephrogenic systemic fibrosis with renal impairment precautions.
Category Scores
Accurate Statements
GADAVIST is not approved for intrathecal use and intrathecal administration can cause serious adverse reactions including death, coma, encephalopathy, and seizures.
Sections 5.1 and 2.2 (IV-only; must not be administered intrathecally; intrathecal safety not established)
GADAVIST is for intravenous use only and must not be administered intrathecally.
Section 2.2
The recommended dose of GADAVIST for adult and pediatric patients, including term neonates, is 0.1 mmol/kg (0.1 mL/kg) administered intravenously.
Section 2.1
GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs; avoid use unless essential and not available with non-contrast MRI or other modalities.
Section 5.2
NSF risk appears highest for chronic severe kidney disease (GFR < 30 mL/min/1.73m^2) and acute kidney injury; risk lower for chronic moderate kidney disease (GFR 30 to 59) and little/if any for chronic mild kidney disease (GFR 60 to 89).
Section 5.2
Prior to administration, screen all patients for renal dysfunction by obtaining a history and/or laboratory tests; serum creatinine/eGFR may not reliably assess renal function in acute kidney injury.
Sections 5.2 and 8.6
For patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration of a GBCA to enhance elimination; usefulness in prevention of NSF is unknown.
Section 5.2 and Section 8.6 (hemodialysis considerations; usefulness unknown)
Unsupported Statements
Contradictions
Important Omissions
No content provided regarding specific adverse reaction lists beyond intrathecal-related serious outcomes (e.g., general GBCA adverse reactions, hypersensitivity, etc.).
Importance:
Moderate
No boxed warning status/content was explicitly assessed (the prompt excerpts did not include an actual boxed warning section).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The cited claims focus on critical administration restrictions (IV-only; not intrathecal) and major renal/NSF risk mitigation guidance, which are directly consistent with the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing broader adverse reaction and boxed-warning context (not provided in the excerpted content).
Suggested Improvement
Include full boxed warning text (if applicable in the full label) and a more complete adverse reactions section if the goal is to summarize safety comprehensively.